Natera CFO Michael Brophy sells $216,029 in company stock By Investing.com

Michael Burkes Brophy, Chief Financial Officer of Natera, Inc. (), sold a total of $216,029 worth of common stock in early August 2026. The sales occurred across two separate transactions, with prices ranging from $267.9893 to $274.22 per share.

On August 3, 2026, Mr. Brophy disposed of 317 shares. This transaction was related to satisfying tax withholding and remittance obligations connected to the vesting of restricted stock units (RSUs) and was executed under a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The following day, August 4, 2026, an additional 478 shares were sold. These sales were carried out pursuant to a Rule 10b5-1 trading plan, which Mr. Brophy adopted on June 9, 2025, and later modified on September 10, 2025.

Following these transactions, Mr. Brophy directly holds 51,637 shares of Natera common stock.The insider sale comes as Natera’s stock trades near its 52-week high of $288.04, with shares delivering a remarkable 98.8% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value—placing it among companies on the Most Overvalued list. InvestingPro subscribers have access to 13 additional exclusive tips and comprehensive financial metrics to help navigate such investment decisions.

In other recent news, Natera Inc. announced that its Signatera test has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR). This certification encompasses the entire Signatera platform, including the assay and related components. Additionally, Natera published data in JAMA Oncology, demonstrating that its Signatera test can predict chemotherapy benefits in liver cancer patients. The study involved 298 patients and was presented at a prominent oncology congress.

Furthermore, Natera has partnered with Aveta Biomics for a Phase 3 clinical trial to evaluate the efficacy of APG-157 in treating head and neck squamous cell carcinoma. This trial will utilize Natera’s Signatera testing to monitor disease progression and treatment response. In analyst news, Bernstein SocGen Group resumed coverage of Natera with an outperform rating, highlighting the company’s potential for increased volumes and reimbursement in minimal residual disease testing. Japan is expected to be a significant market, with anticipated PMDA reimbursement and a commercial launch later this year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.